HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia.
Allogeneic hematopoietic cell transplantation
Bulk/single cell transcriptomics
HLA class II immunopeptidome
HLA-DM
HLA-DO
Hematological malignancies
Journal
Best practice & research. Clinical haematology
ISSN: 1532-1924
Titre abrégé: Best Pract Res Clin Haematol
Pays: Netherlands
ID NLM: 101120659
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
29
03
2024
revised:
13
05
2024
accepted:
27
06
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
4
8
2024
Statut:
ppublish
Résumé
HLA class II antigen presentation is modulated by the activity of the peptide editor HLA-DM and its antagonist HLA-DO, with their interplay controlling the peptide repertoires presented by normal and malignant cells. The role of these molecules in allogeneic hematopoietic cell transplantation (alloHCT) is poorly investigated. Balanced expression of HLA-DM and HLA-DO can influence the presentation of leukemia-associated antigens and peptides targeted by alloreactive T cells, therefore affecting both anti-leukemia immunity and the potential onset of Graft versus Host Disease. We leveraged on a large collection of bulk and single cell RNA sequencing data, available at different repositories, to comprehensively review the level and distribution of HLA-DM and HLA-DO in different cell types and tissues of the human body. The resulting expression atlas will help future investigations aiming to dissect the dual role of HLA class II peptide editing in alloHCT, and their potential impact on its clinical outcome.
Identifiants
pubmed: 39098801
pii: S1521-6926(24)00027-6
doi: 10.1016/j.beha.2024.101561
pii:
doi:
Substances chimiques
HLA-DM antigens
0
HLA-D Antigens
0
HLA-DO antigens
0
Peptides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101561Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.